Maria Osama Muhammad, Shalaby Mostafa, Syme Alasdair, Eliopoulos Nicoletta, Muanza Thierry
Experimental Medicine Department, Faculty of Medicine, McGill University, Montreal, Quebec, Canada; Surgery Department, Faculty of Medicine, McGill University, Montreal, Quebec, Canada; Radiation Oncology Department, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Dawson College, Montreal, Quebec, Canada.
Cytotherapy. 2016 Sep;18(9):1129-45. doi: 10.1016/j.jcyt.2016.06.008. Epub 2016 Jul 14.
Mesenchymal stromal cells (MSCs) have been used to minimize and repair radiation-induced normal tissue injury in the intestine, salivary gland, liver, skin, lungs and cardiac muscle. This study investigated the ability of adipose tissue-derived MSCs (aMSCs) to minimize and/or repair single dose radiation-induced oral mucositis (RIOM).
Syngenic phenotypically and functionally characterized BALB/c mouse aMSCs were implanted intraperitoneally in a RIOM mouse model with different dosing protocols. Response was quantified macroscopically, microscopically and by using different histological and clinically relevant parameters.
Irradiation at 18 Gy generated a self-resolved single-dose RIOM BALB/c mouse model with 5.6 ± 0.3 days mean duration (95% confidence interval (CI) 4.233-7.1 days) and 100% survival rate. Intraperitoneal implantation of 5 doses of 2.5 million freshly cultured syngenic aMSCs significantly and reproducibly reduced RIOM ulcer duration to 1.6 ± 0.3 days (95% CI 0.0233-3.1 days, a 72% reduction in RIOM ulcer duration), ulcer size and ulcer floor epithelial height. The therapeutic benefits were significantly dependent on dose size and frequency, number of doses, and therapy onset time. aMSCs therapy significantly minimized the RIOM-related weight loss, accelerated the weight gain and improved irradiated animals' hydration and nutritional status. aMSCs therapy did not potentiate head and neck cancer in vitro.
Syngenic freshly cultured aMSCs significantly minimized and repaired radiation-induced oral mucositis with a 72% reduction in ulcer duration. aMSCs dose size and frequency, number of doses and therapy onset time are the main keys for optimized therapeutic outcome. aMSCs therapy did not stimulate Head and Neck cancer cell growth in-vitro.
间充质基质细胞(MSCs)已被用于减轻和修复肠道、唾液腺、肝脏、皮肤、肺和心肌等部位的放射性正常组织损伤。本研究调查了脂肪组织来源的间充质基质细胞(aMSCs)减轻和/或修复单次剂量辐射诱导的口腔黏膜炎(RIOM)的能力。
将同基因表型和功能特征明确的BALB/c小鼠aMSCs以不同给药方案腹腔内植入RIOM小鼠模型。通过宏观、微观以及使用不同的组织学和临床相关参数对反应进行量化。
18 Gy照射产生了一种自我缓解的单次剂量RIOM BALB/c小鼠模型,平均持续时间为5.6±0.3天(95%置信区间(CI)4.233 - 7.1天),存活率为100%。腹腔内植入5剂250万个新鲜培养的同基因aMSCs可显著且可重复地将RIOM溃疡持续时间缩短至1.6±0.3天(95% CI 0.0233 - 3.1天,RIOM溃疡持续时间减少72%),并减小溃疡大小和溃疡底部上皮高度。治疗效果显著取决于剂量大小和频率、剂量数量以及治疗开始时间。aMSCs治疗显著减轻了与RIOM相关的体重减轻,加速了体重增加,并改善了受照射动物的水合和营养状况。aMSCs治疗在体外不会增强头颈癌。
同基因新鲜培养的aMSCs可显著减轻和修复辐射诱导的口腔黏膜炎,溃疡持续时间减少72%。aMSCs的剂量大小和频率、剂量数量以及治疗开始时间是优化治疗效果的关键因素。aMSCs治疗在体外不会刺激头颈癌细胞生长。